E2F3 and neoplasm: In the absence of RB1, E2F3 acts as a key driver for cell cycle progression and hence, its overexpression is associated with tumor progression and poor prognosis in Rb patients (Cooper et al., 2006; Madhavan et al., 2009; Gao et al., 2017; Chen et al., 2019).